IGF-1 vs Growth Hormone: Mechanism and Class Compared
IGF-1 and growth hormone are two different molecules that sit in the same endocrine axis. Growth hormone is a pituitary protein that binds the growth hormone receptor; IGF-1 is an insulin-like peptide produced largely in the liver in response to growth hormone, acting through the IGF-1 receptor. Published pharmacology and endocrinology literature describes overlapping growth effects but divergent metabolic actions, different regulatory categories and different measurement roles in conditions such as acromegaly. This page summarises what those studies report.
Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are frequently discussed as if they were interchangeable. They are not the same molecule, and they do not belong to the same structural class. GH is a single-chain pituitary protein of the somatotropin family; IGF-1 is a smaller insulin-like peptide whose structure resembles proinsulin. What links them is a hierarchy: GH released from the anterior pituitary drives production of IGF-1, and much of the growth-promoting signal attributed to GH is carried out by IGF-1 at target tissues. Review literature covering both hormones in the central nervous system described GH and IGF-1 as distinct ligands with distinct receptors that nonetheless converge on overlapping physiological outputs (PMID 40623083).
This page is for educational purposes only and is not medical advice; consult a licensed physician about any hormone, medication or health condition. Nothing here describes how any substance should be used, and no dosing information is provided.
Is IGF-1 a Form of Growth Hormone?
No. The two are separate gene products with separate receptors. Growth hormone is a ~191-amino-acid single-chain protein secreted in pulses by somatotroph cells of the anterior pituitary, and it signals through the growth hormone receptor, a class I cytokine receptor that activates JAK2\u2013STAT5. IGF-1 is a ~70-amino-acid peptide that signals through the IGF-1 receptor, a tyrosine kinase closely related to the insulin receptor. The relationship is sequential rather than synonymous: GH is the upstream pituitary signal, and IGF-1 is the principal downstream mediator measured in blood.
That hierarchy is why clinical endocrinology uses the two measurements differently. A 2025 review of diagnostic challenges in acromegaly described IGF-1 as the integrated marker of GH exposure over time, because GH itself is secreted in pulses that make single random measurements difficult to interpret, while IGF-1 circulates at comparatively stable concentrations (PMID 39757391). In other words, researchers treat IGF-1 as a readout of GH action rather than as GH itself.
Structure, Receptors and Origin Compared
| Feature | Growth hormone (somatotropin) | IGF-1 (somatomedin C) |
|---|---|---|
| Structural class | Four-helix bundle cytokine-fold protein, somatotropin/prolactin family | Single-chain insulin-like peptide, proinsulin-related family |
| Principal source | Anterior pituitary somatotrophs | Liver, plus local tissue production; extra-hepatic sources were described in acromegaly literature (PMID 30349613) |
| Receptor | Growth hormone receptor (class I cytokine receptor) | IGF-1 receptor (receptor tyrosine kinase); CNS actions of both reviewed in 2026 (PMID 40623083) |
| Secretion pattern | Pulsatile, complicating single-sample interpretation (PMID 39757391) | Relatively stable circulating concentrations used as an integrated marker (PMID 39757391) |
| Carrier proteins | Growth hormone binding protein (receptor ectodomain) | IGF binding proteins, predominantly IGFBP-3 with acid-labile subunit |
| Glucose handling | Associated with secondary diabetes mellitus when chronically elevated (PMID 36882643) | Insulin-like signalling through a receptor homologous to the insulin receptor |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhere the Two Signals Diverge
The clearest pharmacological divergence between GH and IGF-1 is metabolic. GH has actions on lipolysis and hepatic glucose output that are not reproduced by IGF-1; IGF-1, by contrast, shares structural and signalling homology with insulin. A 2023 review of secondary diabetes mellitus in acromegaly reported that chronic GH excess is associated with disturbed glucose metabolism and that diabetes is a common comorbidity in that condition, which the authors linked to GH's effects on insulin sensitivity rather than to a simple surplus of growth signalling (PMID 36882643). This is the standard illustration of why the two hormones cannot be treated as one entity: a state of high GH and high IGF-1 produces a metabolic phenotype that is dominated by the GH component.
A second divergence concerns where IGF-1 is made. The classical model holds that circulating IGF-1 is hepatic, produced in response to GH. A review of extra-hepatic acromegaly described clinical presentations in which IGF-1 production arises outside the liver, demonstrating that local tissue IGF-1 can contribute to the acromegalic picture independently of the usual pituitary\u2013hepatic route (PMID 30349613). Autocrine and paracrine IGF-1 is therefore not simply a mirror of pituitary GH output.
A third divergence is anatomical receptor distribution. A 2026 physiology review of GH and IGF-1 actions in the brain described roles for both hormones in central nervous system function and discussed their relevance to neuropsychiatric disease, noting that the two ligands act through separate receptors expressed in brain tissue (PMID 40623083). Because receptor expression differs by tissue, the same upstream stimulus can produce different local outcomes depending on whether GH receptors, IGF-1 receptors or both are present.
What Regulates Each Hormone
Nutrition and dietary protein
IGF-1 concentrations are sensitive to nutritional status in a way that is well documented. A 2014 Cell Metabolism study reported that low protein intake was associated with a major reduction in circulating IGF-1 and with lower cancer and overall mortality in people aged 65 and younger, but not in the older population (PMID 24606898). The study is frequently cited as evidence that IGF-1 is a nutritionally responsive signal rather than a fixed trait.
Diet has also been studied on the GH side of the axis. Researchers reported in a 2026 Cell Metabolism paper that a methionine-supplemented longevity diet increased growth hormone, GLP-1 and FGF21, reduced frailty and promoted healthspan measures (PMID 42335894). Read alongside the protein-restriction work, these two papers illustrate that dietary inputs do not move GH and IGF-1 in lockstep (PMID 24606898, PMID 42335894).
The gut microbiota
A 2018 review in Calcified Tissue International examined the relationship between the gut microbiota and IGF-1, discussing microbiota-dependent influences on IGF-1 and on skeletal outcomes (PMID 29362822). This is a regulatory input described for IGF-1 specifically, and it has no direct equivalent in the classical description of pituitary GH release.
Developmental stage
Both hormones change across the lifespan. A 2019 overview of normal pubertal physiology described the hormonal coordination underlying the pubertal growth spurt, in which the somatotropic axis and gonadal steroids act together (PMID 31000487). The practical consequence noted in endocrine literature is that reference ranges for IGF-1 are age- and puberty-dependent, which is one reason the same absolute value carries different meaning at different ages (PMID 31000487).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRegulatory Status and Class Membership
GH and IGF-1 occupy different regulatory categories. Recombinant human growth hormone has a long approved-product history, and a 2012 review in the Indian Journal of Pediatrics discussed biosimilar growth hormone products and the regulatory expectations applied to them, including the comparability requirements that distinguish a biosimilar from a generic small molecule (PMID 22108957). That review illustrates that GH products are regulated as biologics with defined manufacturing and comparability pathways (PMID 22108957).
Recombinant human IGF-1 exists as a separate approved biologic in a narrow indication (severe primary IGF-1 deficiency), reflecting its position downstream of GH rather than as a substitute for it. Materials sold as research chemicals, including IGF-1 analogues and GH-related peptides, are not approved medicines and are labelled for laboratory research use only. Regulatory classification follows the molecule and its approved indication, not the axis it belongs to.
From a classification standpoint, the question \"is IGF-1 a growth hormone?\" has a clean answer in pharmacological taxonomy: IGF-1 belongs to the insulin/IGF peptide family, while GH belongs to the somatotropin/prolactin cytokine family. They are members of the same physiological axis, not the same class.
Excess GH and IGF-1 Signalling: What Studies Report
Most of what is known about sustained elevation of this axis in humans comes from acromegaly, the syndrome of chronic GH excess, usually from a pituitary somatotroph adenoma. The 2025 review of diagnostic challenges and individualised treatment in acromegaly described a disease course characterised by somatic overgrowth and systemic comorbidity, and emphasised that diagnosis and monitoring rely on IGF-1 measurement interpreted against age-matched ranges (PMID 39757391).
- Glucose metabolism. A 2023 Endocrine review reported that secondary diabetes mellitus is a recognised complication of acromegaly, discussing its mechanisms and management within that disease context (PMID 36882643).
- Male sexual and reproductive health. A 2022 review in Reviews in Endocrine and Metabolic Disorders examined acromegaly and male sexual health, describing associations between the disease and impairments in sexual and gonadal function (PMID 35364803).
- Pregnancy. A 2011 review in Annales d'Endocrinologie addressed acromegaly and pregnancy, covering the interaction between the disease, its management and gestation (PMID 21820101).
- Comparative biology. A 2021 review described acromegaly as it occurs in dogs and cats, providing a veterinary comparison of GH excess across species (PMID 33727117).
These reports concern a pathological disease state, not the effect of any particular product, and they are summarised here only to show which organ systems the literature associates with chronic elevation of the GH\u2013IGF-1 axis (PMID 39757391, PMID 36882643).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeWhat the Comparison Does Not Settle
Comparing GH and IGF-1 side by side does not establish that one is preferable to the other for any purpose, and the literature cited here does not address that question. The papers summarised describe diagnostic use of IGF-1 in disease (PMID 39757391), nutritional and microbial regulation of IGF-1 (PMID 24606898, PMID 29362822), dietary effects on GH (PMID 42335894), and regulatory frameworks for GH biologics (PMID 22108957). None of them compares administered GH to administered IGF-1 head to head in healthy adults. Statements that one hormone is \"stronger\" or \"safer\" than the other are not supported by the sources on this page.
Two further limits are worth noting. First, circulating IGF-1 reflects both hepatic output and binding-protein status, so a single value does not isolate tissue-level signalling, a point reinforced by descriptions of extra-hepatic IGF-1 production (PMID 30349613). Second, association studies linking IGF-1 concentrations to long-term outcomes, such as the 2014 protein-intake analysis, were observational and age-stratified, with findings that differed between younger and older groups (PMID 24606898).
Related Reading
For a molecule-level overview of IGF-1 itself, including its structure, binding proteins and the studies that have measured it, see the PeptideU IGF-1 learn page.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeReferences
- Acromegaly: diagnostic challenges and individualized treatment (Expert Review of Endocrinology & Metabolism, 2025)
- Extra-hepatic Acromegaly (European Endocrinology, 2013)
- Secondary diabetes mellitus in acromegaly (Endocrine, 2023)
- Acromegaly and male sexual health (Reviews in Endocrine & Metabolic Disorders, 2022)
- Acromegaly and pregnancy (Annales d'Endocrinologie, 2011)
- Acromegaly in dogs and cats (Annales d'Endocrinologie, 2021)
- Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases (Physiology, 2026)
- Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population (Cell Metabolism, 2014)
- Methionine-supplemented longevity diet increases growth hormone, GLP-1, and FGF21; reduces frailty; and promotes healthspan (Cell Metabolism, 2026)
- Gut Microbiota and IGF-1 (Calcified Tissue International, 2018)
- Biosimilar growth hormone (Indian Journal of Pediatrics, 2012)
- Puberty: Normal physiology (brief overview) (Best Practice & Research Clinical Endocrinology & Metabolism, 2019)
Frequently asked questions
Is IGF-1 the same thing as HGH?▾
No. Growth hormone is a pituitary protein in the somatotropin family, while IGF-1 is a smaller insulin-like peptide acting through its own tyrosine kinase receptor. They sit in one axis but belong to different molecular families. A 2026 review described both hormones acting in the brain through separate receptors with overlapping physiological outputs (PMID 40623083).
Why do clinicians measure IGF-1 rather than growth hormone?▾
A 2025 review of acromegaly diagnosis reported that growth hormone is secreted in pulses, making single random measurements hard to interpret, whereas IGF-1 circulates more stably and serves as an integrated marker of growth hormone exposure over time (PMID 39757391). Reference ranges are age-dependent, which the pubertal physiology literature also reflects (PMID 31000487).
Do growth hormone and IGF-1 affect blood sugar the same way?▾
The literature describes a divergence here. A 2023 review reported that secondary diabetes mellitus is a recognised comorbidity of acromegaly, a state of chronic growth hormone excess, and discussed its mechanisms and management (PMID 36882643). IGF-1, by contrast, signals through a receptor structurally homologous to the insulin receptor, giving it insulin-like rather than counter-regulatory characteristics.
Is all IGF-1 made by the liver in response to growth hormone?▾
Not entirely. While hepatic production driven by growth hormone accounts for most circulating IGF-1, a review of extra-hepatic acromegaly described presentations in which IGF-1 production arises outside the liver (PMID 30349613). Local autocrine and paracrine IGF-1 therefore does not always mirror pituitary growth hormone output, which complicates reading blood IGF-1 as a single signal.
Does diet change IGF-1 and growth hormone in the same direction?▾
The cited studies suggest not necessarily. A 2014 study reported that low protein intake was associated with a major reduction in IGF-1 and with lower cancer and overall mortality in people aged 65 and younger but not older (PMID 24606898). Separately, researchers reported that a methionine-supplemented longevity diet increased growth hormone, GLP-1 and FGF21 while reducing frailty (PMID 42335894).
How are growth hormone products regulated?▾
Recombinant human growth hormone is regulated as a biologic. A 2012 review discussed biosimilar growth hormone and the comparability requirements regulators apply, which differ from generic small-molecule pathways (PMID 22108957). Recombinant IGF-1 is a separate approved biologic with its own narrow indication, and research-chemical peptides are not approved medicines. This page is educational and not medical or legal advice.
What does the literature say about chronic excess in this axis?▾
Most human evidence comes from acromegaly. Reviews described somatic overgrowth and systemic comorbidity requiring individualised treatment (PMID 39757391), associations with impaired male sexual health (PMID 35364803), specific considerations in pregnancy (PMID 21820101), and comparable disease in dogs and cats (PMID 33727117). These describe a disease state, not the effect of any product.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.